Modelling shows dabigatran benefit

UK experts in pharmacology and statistics, funded by the Medical Research Council, compared costs and quality-adjusted life years (QALYs) gained among 50,000 simulated patients, at moderate to high risk of stroke,
treated with 110 mg or 150 mg of dabigatran twice daily compared to warfarin.

The study extrapolated the findings of the pivotal two-year RE-LY (Randomised Evaluation of Long-Term Anticoagulation Therapy) study to simulate what would happen to patients over a lifetime.

“This analysis supports regulatory decisions that dabigatran offers a positive benefit to harm ratio when compared to warfarin,” the authors said.

“However, no subgroup for which dabigatran 110 mg offered any clinical or economic advantage over 150 mg was identified.

“High dose dabigatran will be cost effective only for patients at increased risk of stroke or for whom international normalised ratio is likely to be less well